Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Jason Sagert et al.|Molecular Cancer Therapeutics|2022Cited by 35
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0